The ACR is aware of the emerging concerns surrounding access to needed treatments, such as methotrexate, after the recent decision in Dobbs v. Jackson Women’s Health Organization. We are following this issue closely to determine if rheumatologists and rheumatology providers and patients are experiencing any widespread difficulty accessing methotrexate, and if any initial disruptions are potentially temporary and due to the independent actions of pharmacists trying to figure out what is and isn’t allowed where they practice.
You Might Also Like
Also By This Author
The ACR opposes any action that interferes with the practice of evidence-based medicine or intrudes upon the doctor-patient relationship. Pregnancy often complicates the management of women with rheumatic diseases and may threaten the life of the mother. Rheumatologists and other rheumatology professionals must be able to provide the best evidence-based care and guidance for all of their patients.
A task force of medical and policy experts has been assembled by the ACR to determine the best course of action to ensure our patients keep access to the treatments they need. In the meantime, we are asking members and patients who have experienced challenges accessing methotrexate to email [email protected] with details.
Learn about the ACR’s Reproductive Health Initiative.